Clinical Trials Browser

Phase 1 × axicabtagene ciloleucel × Clear all

NCT07052305 2026-02-12

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Phase 1 Recruiting

Lymphoma, Non-Hodgkin

NCT05077527 2026-02-09

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, Large B-Cell, Diffuse

NCT05075603 2025-10-23

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT05794958 2025-09-23

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Phase 1 Recruiting

Lymphoma, Non-Hodgkin

NCT04608487 2025-07-30

Axi-cel in CNS Lymphoma

Phase 1 Active not recruiting

Lymphoma, Recurrence